Results 151 to 160 of about 3,046 (215)

Probing relaxed myosin states in hypertrophic cardiomyopathy by second harmonic-generation microscopy. [PDF]

Elife
Arecchi G, Dente M, Ma W, Scellini B, Piroddi N, Scardigli M, Yu J, Zhao J, Cicchi R, Kinegawa R, Muellenbroich C, Sera F, Poggesi C, Ferrantini C, Irving TC, Regnier M, Sacconi L, Tesi C.   +17 more
europepmc   +1 more source

Isolated posterior mitral leaflet elongation as a rare mechanism of systolic anterior motion in hypertrophic cardiomyopathy: a case report of successful treatment with mavacamten. [PDF]

Eur Heart J Case Rep
Gomez LE, Buonfiglio PI, Ackerman J, Bruque CD, Atamañuk AN.   +4 more
europepmc   +1 more source

Efficacy of Mavacamten on functional capacity in hypertrophic cardiomyopathy: a meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials. [PDF]

Ann Med Surg (Lond)
Khalil I, Sheikh A, Nur N, Hossain I, Akter M, Al-Badri SG.   +5 more
europepmc   +1 more source

Rifampicin for the treatment of a cardiogenic shock related to mavacamten toxicity: the worse and the best of drug interactions from a case report. [PDF]

Eur Heart J Case Rep
Lucas S, Hennart B, de Groote P, Lamblin N, Ridon H, Dupre C, Lionet A, Lemesle G.   +7 more
europepmc   +1 more source

Left Atrial Volume Index, Left Ventricular Outflow Tract Gradient, and Incident Atrial Fibrillation in Hypertrophic Cardiomyopathy. [PDF]

Echocardiography
Salman O, Pradeep AG, Purkayastha S, Parikh V, Stahl EP.   +4 more
europepmc   +1 more source

Forward Dynamics: Modern Insights into Mitral Systolic Anterior Motion. [PDF]

J Cardiovasc Dev Dis
Samet Bouhaik FZ, Monaco I, Sedrati M, Bouvet A, Gervais B, Trivelloni V, Bencharef Y, Sekkal FM, Bottigliero D.   +8 more
europepmc   +1 more source

Cardiogenic shock and atrial fibrillation after mavacamten dose escalation in obstructive hypertrophic cardiomyopathy: a case report. [PDF]

Eur Heart J Case Rep
Jeong WJ, Kim SE, Cho SW, Namgung J, Ko KY.   +4 more
europepmc   +1 more source

Mavacamten inhibits myosin activity by stabilizing the myosin interacting-heads motif and stalling motor force generation. [PDF]

Sci Adv
McMillan SN, Pitts JRT, Barua B, Winkelmann DA, Scarff CA.   +4 more
europepmc   +1 more source

Obstructive Hypertrophic Cardiomyopathy in a Symptomatic Professional Athlete Treated With Mavacamten. [PDF]

JACC Case Rep
Bavishi A, Marella D, Kim JH, Martinez MW.   +3 more
europepmc   +1 more source